Multi‐wall carbon nanotubes – a vehicle for targeted Irinotecan drug delivery
- 26 August 2010
- journal article
- research article
- Published by Wiley in Physica Status Solidi (b)
- Vol. 247 (11-12) , 2673-2677
Abstract
Chemotherapeutics, administered to defeat neoplastic disease, generally interfere with the growth of cancer cells, eventually destroying them. Since the growth of normal cells may also be affected, serious adverse effects may occur. In addition, many medications might not be properly delivered to the target area because of susceptibility to precocious enzymatic degradation in the systemic circulation. An attractive method to safely deliver anticancer drugs to targeted tissues is to employ carbon nanotubes (CNTs) as a transport vehicle. Here we present a study on the encapsulation of the antineoplastic agent Irinotecan within multi‐wall carbon nanotubes (MWCNTs). We also study the pH‐dependent release of the guest molecules from the nanotubes cavity to phosphate and acetate buffers. magnified image Schematic representation of Irinotecan filled MWCNTs.Keywords
This publication has 12 references indexed in Scilit:
- Single-wall carbon nanotubes based anticancer drug delivery systemChemical Physics Letters, 2009
- Modifying CVD synthesised carbon nanotubes via the carbon feed ratePhysica E: Low-dimensional Systems and Nanostructures, 2008
- Carbon Nanotubes Filled with a Chemotherapeutic Agent: A Nanocarrier Mediates Inhibition of Tumor Cell GrowthNanomedicine, 2008
- Synthesis and characteristics of Fe-filled multi-walled carbon nanotubes for biomedical applicationJournal of Physics: Conference Series, 2007
- Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivoBiochimica et Biophysica Acta (BBA) - Biomembranes, 2007
- Effect of Composition on the stability of liposomal irinotecan prepared by a pH gradient methodJournal of Bioscience and Bioengineering, 2003
- Photodegradation of Irinotecan (CPT-11) in Aqueous Solutions: Identification of Fluorescent Products and Influence of Solution CompositionJournal of Pharmaceutical Sciences, 1997
- Characterisation and Clinical Management of CPT-11 (Irinotecan)-induced Adverse Events: The European PerspectiveEuropean Journal of Cancer, 1996
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994
- Large-scale synthesis of carbon nanotubesNature, 1992